The University of Melbourne-headquartered Bio21 will add a new building, with biotherapeutics company CSL beefing up its research presence at the Parkville research hub.
Business Spectator and others report that the expansion was announced yesterday, with a new building at the $36.4 million hub to be constructed and then opened next year.
CSL, the anchor tenant at the new building, would put $14 million towards the site and would increase the number of scientists from 75 to about 150 at Bio21, it said.
“Our research scientists find Bio21 an attractive and intellectually stimulating place to work, and the cross-cultivation of ideas from academia to commercial helps translate science into lifesaving medicines,” Business Spectator reports R&D head Andrew Cuthbertson as saying.
“R&D is our past and our future. The increased presence at Bio21 will allow CSL to increase its collaborations with university researchers, plus other research institutes and hospitals. It will also provide an expanded base for new national and international collaborations.”
CSL has been a partner at Bio21 since 2007, and efforts there have included a vaccine against gum disease, reports The Herald Sun.
Elsewhere, AAP reports that the company’s new Idelvion, a treatment for a shortage of factor IX protein in haemophilia B sufferes, has received FDA approval in the United States. It has already been approved in Canada, Switzerland and Japan.